{"id":{"repo_id":"whiterose","oai_identifier":"oai:etheses.whiterose.ac.uk:31442"},"canonical_url":"https://search.ndltd.org/etd/whiterose/oai:etheses.whiterose.ac.uk:31442","repository":{"repo_id":"whiterose","name":"White Rose University Consortium","base_url":"https://etheses.whiterose.ac.uk/cgi/oai2"},"display":{"title":"Mitochondrial dysfunction as a therapeutic target in Parkinson's Disease","abstract":null,"abstract_html":null,"abstract_has_math":false,"creators":["Payne, Thomas"],"institution":"University of Sheffield","degree_name":"Ph.D","degree_level":"doctoral","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Bandmann, Oliver","Jenkins, Thomas","Mortiboys, Heather"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-04","date_published":"2022-04","updated_at":"2026-11-18T23:19:31Z","subjects":[],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000167537847"],"render_values":[{"text":"0000-0001-6753-7847","href":"https://orcid.org/0000-0001-6753-7847","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"https://etheses.whiterose.ac.uk/id/eprint/31442/1/Thesis%20Final%20Corrected.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.whiterose.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.whiterose.ac.uk%3A31442","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bandmann, Oliver","Jenkins, Thomas","Mortiboys, Heather"]},{"key":"dc:contributor.sponsor","label":"Sponsor","values":["Cure Parkinson's Trust","Michael J Fox Foundation","The Jon Moulton Charity Trust"]},{"key":"dc:creator","label":"Author","values":["Payne, Thomas"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000167537847"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-04"]},{"key":"dc:date.issued","label":"Date","values":["2022-04"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Medicine (Sheffield)"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Sheffield"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://etheses.whiterose.ac.uk/id/eprint/31442/"]},{"key":"dc:relation.references","label":"Dc Relation References","values":["1. Dorsey, E.R., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384-386 (2007). 2. Kalia, L.V. & Lang, A.E. Parkinson's disease. The Lancet 386, 896-912 (2015). 3. Findley, L.J., et al. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 14, 130-139 (2011). 4. Lees, A. An essay on the shaking palsy. Brain 140, 843-848 (2017). 5. Schapira, A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54, 823-827 (1990). 6. van der Brug, M.P., Singleton, A., Gasser, T. & Lewis, P.A. Parkinson's disease: From human genetics to clinical trials. Sci Transl Med 7, 205ps220 (2015). 7. Schapira, A.H., Olanow, C.W., Greenamyre, J.T. & Bezard, E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545-555 (2014). 8. Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T.D. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29, 1583-1590 (2014). 9. Collaborators, G.B.D.P.s.D. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17, 939-953 (2018). 10. Heinzel, S., et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 34, 1464-1470 (2019). 11. Berg, D., et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 30, 1600-1611 (2015). 12. Gibb, W.R. & Lees, A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51, 745-752 (1988). 13. Hughes, A.J., Daniel, S.E., Kilford, L. & Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184 (1992). 14. Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y. & Lees, A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861-870 (2002). 15. Wojtala, J., et al. Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. J Neurol Neurosurg Psychiatry 90, 171-179 (2019). 16. Post, B., Merkus, M.P., de Haan, R.J., Speelman, J.D. & Group, C.S. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 22, 1839-1851; quiz 1988 (2007). 17. Velseboer, D.C., et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 86, 986-993 (2016). 18. Mancini, M., et al. Trunk accelerometry reveals postural instability in untreated Parkinson's disease. Parkinsonism Relat Disord 17, 557-562 (2011). 19. Knudsen, K., Krogh, K., Ostergaard, K. & Borghammer, P. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Mov Disord 32, 94-105 (2017). 20. Adams-Carr, K.L., et al. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 87, 710-716 (2016). 21. Zhang, J., Xu, C.Y. & Liu, J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. BMC Neurol 17, 23 (2017). 22. Postuma, R.B., et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744-759 (2019). 23. Zis, P., Erro, R., Walton, C.C., Sauerbier, A. & Chaudhuri, K.R. The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 1, 15013 (2015). 24. Riedel, O., et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. Journal of Neurology 257, 1073-1082 (2010). 25. Wood, R.A., Hopkins, S.A., Moodley, K.K. & Chan, D. Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients. Front Neurol 6, 263 (2015). 26. Goetz, C.G., Stebbins, G.T. & Ouyang, B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord 26, 2196-2200 (2011). 27. Factor, S.A., et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. Journal of the neurological sciences 347, 316-321 (2014). 28. Broeders, M., et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology 81, 346-352 (2013). 29. Hobson, P. & Meara, J. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. International Journal of Geriatric Psychiatry 30, 1048-1055 (2015). 30. Aarsland, D., Zaccai, J. & Brayne, C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 20, 1255-1263 (2005). 31. Galtier, I., Nieto, A., Lorenzo, J.N. & Barroso, J. Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study. J Neurol 266, 745-754 (2019). 32. Vossius, C., Larsen, J.P., Janvin, C. & Aarsland, D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 26, 1541-1544 (2011). 33. Macleod, A.D., Taylor, K.S. & Counsell, C.E. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29, 1615-1622 (2014). 34. Dommershuijsen, L.J., et al. Life expectancy of parkinsonism patients in the general population. Parkinsonism Relat Disord 77, 94-99 (2020). 35. LeWitt, P.A. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64-72 (2015). 36. Group, T.P.S. Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine 351, 2498-2508 (2004). 37. Verschuur, C.V.M., et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. New England Journal of Medicine 380, 315-324 (2019). 38. Rossi, C., Del Prete, E. & Bonuccelli, U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease AU - Ceravolo, Roberto. Expert Opinion on Drug Safety 15, 181-198 (2016). 39. Kordower, J.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419-2431 (2013). 40. Braak, H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211 (2003). 41. Lautenschlager, J., et al. C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun 9, 712 (2018). 42. Diao, J., et al. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2, e00592 (2013). 43. Man, W.K., et al. The docking of synaptic vesicles on the presynaptic membrane induced by alpha-synuclein is modulated by lipid composition. Nat Commun 12, 927 (2021). 44. Parkkinen, L., Kauppinen, T., Pirttila, T., Autere, J.M. & Alafuzoff, I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57, 82-91 (2005). 45. Klos, K.J., et al. α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66, 1100-1102 (2006). 46. Polymeropoulos, M.H., et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease. Science 276, 2045-2047 (1997). 47. Book, A., et al. A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. Frontiers in Neurology 9(2018). 48. Trinh, J., et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33, 1857-1870 (2018). 49. Kalia, L.V., et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72, 100-105 (2015). 50. Sidransky, E., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361, 1651-1661 (2009). 51. Winder-Rhodes, S.E., et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136, 392-399 (2013). 52. Gegg, M.E., et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72, 455-463 (2012). 53. Friedman, J.R. & Nunnari, J. Mitochondrial form and function. Nature 505, 335-343 (2014). 54. Chaban, Y., Boekema, E.J. & Dudkina, N.V. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta 1837, 418-426 (2014). 55. Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L. & Neuzil, J. Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta 1827, 552-564 (2013). 56. Kadenbach, B. Complex IV - The regulatory center of mitochondrial oxidative phosphorylation. Mitochondrion 58, 296-302 (2021). 57. Chen, G., Kroemer, G. & Kepp, O. Mitophagy: An Emerging Role in Aging and Age-Associated Diseases. Front Cell Dev Biol 8, 200 (2020). 58. Eisner, V., Picard, M. & Hajnoczky, G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat Cell Biol 20, 755-765 (2018). 59. Kleele, T., et al. Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature 593, 435-439 (2021). 60. Langston, J., Ballard, P., Tetrud, J. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983). 61. Chiueh, C.C., et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 20, 548-553 (1984). 62. Nguyen, T.N., Padman, B.S. & Lazarou, M. Deciphering the Molecular Signals of PINK1/Parkin Mitophagy. Trends in Cell Biology 26, 733-744 (2016). 63. Su, Y.C. & Qi, X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet. 15, 4545-4561 (2013). 64. Mortiboys, H., Johansen, K.K., Aasly, J.O. & Bandmann, O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 2017-2020 (2010). 65. Girotto, S., et al. Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53. J Biol Chem 287, 18738-18749 (2012). 66. Toulorge, D., Schapira, A.H. & Hajj, R. Molecular changes in the postmortem parkinsonian brain. J Neurochem 139 Suppl 1, 27-58 (2016). 67. Wang, X., et al. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathologica Communications 7, 41 (2019). 68. Shahmoradian, S.H., et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nature Neuroscience 22, 1099-1109 (2019). 69. Sian, J., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36, 348-355 (1994). 70. Zhang, J., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. The American journal of pathology 154, 1423-1429 (1999). 71. Coxhead, J., et al. Somatic mtDNA variation is an important component of Parkinson's disease. Neurobiol Aging 38, 217 e211-217 e216 (2016). 72. Pyle, A., et al. Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. Neurobiol Aging 38, 216 e217-216 e210 (2016). 73. Schwartzentruber, A., et al. Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons. Sci Rep 10, 15485 (2020). 74. Hou, X., et al. Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy 14, 1404-1418 (2018). 75. Hruska, K.S., LaMarca, M.E., Scott, C.R. & Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29, 567-583 (2008). 76. Mazzulli, J.R., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011). 77. McNeill, A., et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481-1495 (2014). 78. Goker-Alpan, O., Stubblefield, B.K., Giasson, B.I. & Sidransky, E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120, 641-649 (2010). 79. Anderson, J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752 (2006). 80. Sanjeev, A. & Mattaparthi, V.S.K. Computational investigation on the effects of H50Q and G51D mutations on the α-Synuclein aggregation propensity. Journal of Biomolecular Structure and Dynamics 36, 2224-2236 (2018). 81. Hayakawa, H., et al. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology. Movement disorders : official journal of the Movement Disorder Society 35, 256-267 (2020). 82. Lashuel, H.A., et al. α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal of Molecular Biology 322, 1089-1102 (2002). 83. Li, J.-Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 14, 501-503 (2008). 84. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 14, 504-506 (2008). 85. Desplats, P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 106, 13010-13015 (2009). 86. Masuda-Suzukake, M., et al. Prion-like spreading of pathological α-synuclein in brain. Brain : a journal of neurology 136, 1128-1138 (2013). 87. Hilton, D., et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathologica 127, 235-241 (2014). 88. Stokholm, M.G., Danielsen, E.H., Hamilton-Dutoit, S.J. & Borghammer, P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Annals of Neurology 79, 940-949 (2016). 89. Van Den Berge, N., et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 138, 535-550 (2019). 90. Kim, S., et al. Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron 103, 627-641 e627 (2019). 91. Gao, X., Chen H Fau - Schwarzschild, M.A., Schwarzschild Ma Fau - Ascherio, A. & Ascherio, A. Use of ibuprofen and risk of Parkinson disease. Neurology 76, 863-869 (2011). 92. Racette, B.A., et al. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol 5, 870-875 (2018). 93. McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291 (1988). 94. Gerhard, A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of disease 21, 404-412 (2006). 95. Williams-Gray, C.H., et al. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord 31, 995-1003 (2016). 96. Greenland, J.C., et al. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open 10, e040527 (2020). 97. Marras, C., Lang, A.E., Austin, P.C., Lau, C. & Urbach, D.R. Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. Mov Disord 31, 1243-1247 (2016). 98. Kim, R., Lee, J.Y., Park, S., Han, K. & Shin, C.M. Cholecystectomy and subsequent risk of Parkinson's disease: a nationwide retrospective cohort study. NPJ Parkinsons Dis 7, 100 (2021). 99. Malagelada, J.R., Go, V.L.W., Summerskill, W.H.J. & Gamble, W.S. Bile acid secretion and biliary bile acid composition altered by cholecystectomy. The American Journal of Digestive Diseases 18, 455-459 (1973). 100. Hepner, G.W., Hofmann, A.F., Malagelada, J.R., Szczepanik, P.A. & Klein, P.D. Increased Bacterial Degradation of Bile Acids in Cholecystectomized Patients. Gastroenterology 66, 556-564 (1974). 101. Kullak-Ublick, G.-A., Paumgartner, G. & Berr, F. Long-term effects of cholecystectomy on bile acid metabolism. Hepatology 21, 41-45 (1995). 102. Chen, M.L., Takeda, K. & Sundrud, M.S. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunology 12, 851-861 (2019). 103. Pavlidis, P., et al. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Alimentary Pharmacology & Therapeutics 42, 802-817 (2015). 104. Grant, S.M. & DeMorrow, S. Bile Acid Signaling in Neurodegenerative and Neurological Disorders. Int J Mol Sci 21, 5982 (2020). 105. Huang, F., et al. Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior. Front Behav Neurosci 9, 70-70 (2015). 106. McMillin, M., et al. TGR5 signaling reduces neuroinflammation during hepatic encephalopathy. Journal of neurochemistry 135, 565-576 (2015). 107. McMillin, M., et al. Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice. Frontiers in cellular neuroscience 11, 191-191 (2017). 108. Romano, S., et al. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 7, 27 (2021). 109. Li, P., et al. Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. Metabolites 11(2021). 110. Shao, Y., et al. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Mol Neurodegener 16, 4 (2021). 111. Graham, S.F., et al. Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson's Disease. Metabolites 8(2018). 112. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46, 1052-1060 (1989). 113. Snow, B.J., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25, 1670-1674 (2010). 114. The Parkinson Study Group QE3 Investigators, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71, 543-552 (2014). 115. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313, 584-593 (2015). 116. The Parkinson Study Group SURE-PD3 Investigators, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA 326, 926-939 (2021). 117. Jankovic, J., et al. Variable expression of Parkinson's disease. A base‐line analysis of the DAT ATOP cohort 40, 1529-1529 (1990). 118. Stebbins, G.T., et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 28, 668-670 (2013). 119. Alves, G., Larsen, J.P., Emre, M., Wentzel-Larsen, T. & Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Movement Disorders 21, 1123-1130 (2006). 120. Simuni, T., et al. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 28, 62-67 (2016). 121. Aleksovski, D., Miljkovic, D., Bravi, D. & Antonini, A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39, 1971-1976 (2018). 122. Goetz, C.G., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23, 2129-2170 (2008). 123. Post, B., Merkus, M.P., de Bie, R.M., de Haan, R.J. & Speelman, J.D. Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord 20, 1577-1584 (2005). 124. Chaudhuri, K.R., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 22, 1901-1911 (2007). 125. Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age and ageing 26, 353-357 (1997). 126. Del Din, S., et al. Gait analysis with wearables predicts conversion to parkinson disease. Ann Neurol 86, 357-367 (2019). 127. Buckley, C., Galna, B., Rochester, L. & Mazzà, C. Upper body accelerations as a biomarker of gait impairment in the early stages of Parkinson’s disease. Gait & Posture 71, 289-295 (2019). 128. Rehman, R.Z.U., et al. Accelerometry-Based Digital Gait Characteristics for Classification of Parkinson's Disease: What Counts? IEEE Open Journal of Engineering in Medicine and Biology 1, 65-73 (2020). 129. Wilson, J., et al. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 36, 611-621 (2021). 130. Wilson, J., et al. Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology. Frontiers in Aging Neuroscience 12(2020). 131. Kluge, A.F., et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorganic & Medicinal Chemistry Letters 28, 2655-2659 (2018). 132. Prasuhn, J., et al. An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol Res Pract 1, 31 (2019). 133. Gmitterova, K., et al. 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases. Neuro-degenerative diseases 6, 263-269 (2009). 134. Abe, T., Isobe, C., Murata, T., Sato, C. & Tohgi, H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 336, 105-108 (2003). 135. Mortiboys, H., et al. Translational approaches to restoring mitochondrial function in Parkinson's disease. FEBS Lett 592, 776-792 (2018). 136. Lewitt, P.A., et al. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord 28, 1653-1660 (2013). 137. Konings, C.H., et al. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. Journal of the neurological sciences 168, 112-115 (1999). 138. Waragai, M., et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochemical and biophysical research communications 345, 967-972 (2006). 139. Herbert, M.K., et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20, 112-115 (2014). 140. Hong, Z., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010). 141. Shi, M., et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480, 78-82 (2010). 142. Waragai, M., et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425, 18-22 (2007). 143. Maita, C., et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431, 86-89 (2008). 144. Chen, C.M., et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiology of disease 33, 429-435 (2009). 145. Shukla, R., Rajani, M., Srivastava, N., Barthwal, M.K. & Dikshit, M. Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. The International journal of neuroscience 116, 1391-1402 (2006). 146. Burte, F., et al. metabolic profiling of Parkinson's disease and mild cognitive impairment. Mov Disord 32, 927-932 (2017). 147. Pyle, A., et al. Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. Ann Neurol 78, 1000-1004 (2015). 148. Podlesniy, P., et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology 74, 655-668 (2013). 149. Podlesniy, P., et al. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiology of disease 94, 10-17 (2016). 150. Davis, R.L., et al. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 81, 1819-1826 (2013). 151. Davis, R.L., Liang, C. & Sue, C.M. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 86, 2010-2015 (2016). 152. Yao, X., et al. Serum Growth Differentiation Factor 15 in Parkinson Disease. Neuro-degenerative diseases 17, 251-260 (2017). 153. Davis, R.L., et al. Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. Neurol Clin Pract 10, 40-46 (2020). 154. Shen, C., Guo, Y., Luo, W., Lin, C. & Ding, M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 40, 73-79 (2013). 155. Gao, X., O'Reilly, É.J., Schwarzschild, M.A. & Ascherio, A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86, 520-526 (2016). 156. Ascherio, A., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66, 1460-1468 (2009). 157. Koros, C., et al. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism & Related Disorders 84, 1-4 (2021). 158. Koros, C., et al. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson’s Disease: Data from the PPMI Study. Journal of Parkinson's Disease 10, 481-487 (2020). 159. Mortiboys, H., et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 64, 555-565 (2008). 160. Auburger, G., et al. Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol 46, 20-27 (2012). 161. Carling, P.J., et al. Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease. Prog Neurobiol 187, 101772 (2020). 162. Meyer, K., et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A 111, 829-832 (2014). 163. Mertens, J., et al. Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. Cell Stem Cell 17, 705-718 (2015). 164. Milanese, C., et al. Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease. Mov Disord 34, 1192-1202 (2019). 165. de Graaf, R.A. Basic Principles. in In Vivo NMR Spectroscopy 1-42 (John Wiley & Sons, Ltd., 2019). 166. de Graaf, R.A. In Vivo NMR Spectroscopy – Static Aspects. in In Vivo NMR Spectroscopy 43-128 (John Wiley & Sons, Ltd., 2019). 167. de Graaf, R.A. In Vivo NMR Spectroscopy – Dynamic Aspects. in In Vivo NMR Spectroscopy 129-210 (John Wiley & Sons, Ltd., 2019). 168. de Graaf, R.A. Magnetic Resonance Imaging. in In Vivo NMR Spectroscopy 211-252 (John Wiley & Sons, Ltd., 2019). 169. de Graaf, R.A. Radiofrequency Pulses. in In Vivo NMR Spectroscopy 253-291 (John Wiley & Sons, Ltd., 2019). 170. de Graaf, R.A. Spectroscopic Imaging and Multivolume Localization. in In Vivo NMR Spectroscopy 335-373 (John Wiley & Sons, Ltd., 2019). 171. Boer, V.O. & Klomp, D.W.J. Chapter 1.3 - Technical Considerations for Multivoxel Approaches and Magnetic Resonance Spectroscopic Imaging. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 31-39 (Academic Press, San Diego, 2014). 172. de Graaf, R.A. Chapter 1.4 - Spectral Editing and 2D NMR. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 40-48 (Academic Press, San Diego, 2014). 173. Juchem, C. & Rothman, D.L. Chapter 1.1 - Basis of Magnetic Resonance. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 3-14 (Academic Press, San Diego, 2014). 174. Lei, H., Xin, L., Gruetter, R. & Mlynárik, V. Chapter 1.2 - Localized Single-Voxel Magnetic Resonance Spectroscopy, Water Suppression, and Novel Approaches for Ultrashort Echo-Time Measurements. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 15-30 (Academic Press, San Diego, 2014). 175. Near, J. Chapter 1.5 - Spectral Quantification and Pitfalls in Interpreting Magnetic Resonance Spectroscopic Data: What To Look Out For. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 49-67 (Academic Press, San Diego, 2014). 176. Thulborn, K.R. & Atkinson, I.C. Chapter 4.1 - Quantitative Metabolic Magnetic Resonance Imaging of Sodium, Oxygen, Phosphorus and Potassium in the Human Brain: A Rationale for Bioscales in Clinical Applications. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 291-311 (Academic Press, San Diego, 2014). 177. Blüml, S. Magnetic Resonance Spectroscopy: Basics. in MR Spectroscopy of Pediatric Brain Disorders 11-23 (2013). 178. Weinberg, B.D., Kuruva, M., Shim, H. & Mullins, M.E. Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment. Radiol Clin North Am 59, 349-362 (2021). 179. Rijpma, A., van der Graaf, M., Meulenbroek, O., Olde Rikkert, M.G.M. & Heerschap, A. Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional (31)P MR spectroscopic imaging study. NeuroImage. Clinical 18, 254-261 (2018). 180. Sassani, M., et al. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain 143, 3603-3618 (2020). 181. Hu, M.T.M., et al. Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31P-MRS and 18FDG-PET study. Brain 123, 340-352 (2000). 182. Provencher, S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14, 260-264 (2001). 183. Vanhamme, L., van den Boogaart, A. & Van Huffel, S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129, 35-43 (1997). 184. Barbiroli, B., Iotti, S. & Lodi, R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 9, 253-260 (1999). 185. Barbiroli, B., et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 14, 430-435 (1999). 186. Belanger, M., Allaman, I. & Magistretti, P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14, 724-738 (2011). 187. Rango, M., Bonifati, C. & Bresolin, N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26, 283-290 (2006). 188. Rango, M., Dossi, G., Squarcina, L. & Bonifati, C. Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation. Mov Disord 35, 504-507 (2020). 189. Hattingen, E., et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132, 3285-3297 (2009). 190. Bottomley, P.A. & Hardy, C.J. Rapid, reliable in vivo assays of human phosphate metabolites by nuclear magnetic resonance. Clin Chem 35, 392-395 (1989). 191. Hilker, R., et al. The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations. PLoS One 7, e51308 (2012). 192. Weiduschat, N., et al. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 25, 105-110 (2015). 193. Weiduschat, N., et al. Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism Relat Disord 20, 545-548 (2014). 194. Cai, R., et al. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest 129, 4539-4549 (2019). 195. Schultz, J.L., et al. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord 94, 79-83 (2022). 196. Sathe, A.G., et al. Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. J Clin Pharmacol 60, 744-750 (2020). 197. Lei, H., Ugurbil, K. & Chen, W. Measurement of unidirectional Pi to ATP flux in human visual cortex at 7 T by using in vivo 31P magnetic resonance spectroscopy. Proceedings of the National Academy of Sciences of the United States of America 100, 14409-14414 (2003). 198. Nabuurs, C., Huijbregts, B., Wieringa, B., Hilbers, C.W. & Heerschap, A. 31P saturation transfer spectroscopy predicts differential intracellular macromolecular association of ATP and ADP in skeletal muscle. The Journal of biological chemistry 285, 39588-39596 (2010). 199. Peng, J., Liu, Q., Rao, M.S. & Zeng, X. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen 18, 522-533 (2013). 200. Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136, 3038-3050 (2013). 201. Mortiboys, H., et al. UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85, 846-852 (2015). 202. Chun, H.S. & Low, W.C. Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology 292, 105-112 (2012). 203. Abdelkader, N.F., Safar, M.M. & Salem, H.A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. Mol Neurobiol 53, 810-817 (2016). 204. Castro-Caldas, M., et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol 46, 475-486 (2012). 205. Greene, L.A., Levy, O. & Malagelada, C. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol 31, 969-978 (2011). 206. Abbas, G. & Lindor, K.D. Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert opinion on pharmacotherapy 11, 387-392 (2010). 207. Lazaridis, K.N., Gores, G.J. & Lindor, K.D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 35, 134-146 (2001). 208. Bell, S.M., et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease. J Mol Biol 430, 3942-3953 (2018). 209. Parry, G.J., et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clinical neuropharmacology 33, 17-21 (2010). 210. Kim, H.M., et al. Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. Clin Park Relat Disord 1, 91-97 (2019). 211. Tomlinson, C.L., et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25, 2649-2653 (2010). 212. Holden, S.K., Finseth, T., Sillau, S.H. & Berman, B.D. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Mov Disord Clin Pract 5, 47-53 (2018). 213. Hoehn, M.M. & Yahr, M.D. Parkinsonism: onset, progression and mortality. Neurology 17, 427-442 (1967). 214. Goetz, C.G., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19, 1020-1028 (2004). 215. Blauwendraat, C., et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging 57, 247 e249-247 e213 (2017). 216. RA, d.G. Spectral Quantification. in In Vivo MR Spectroscopy 445-477 (John Wiley & Sons, Ltd, 2007). 217. Wilson, M., et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magn Reson Med 82, 527-550 (2019). 218. Cichocka, M., Kozub, J. & Urbanik, A. PH Measurements of the Brain Using Phosphorus Magnetic Resonance Spectroscopy ((31)PMRS) in Healthy Men - Comparison of Two Analysis Methods. Polish journal of radiology 80, 509-514 (2015). 219. Iotti, S., et al. In vivo assessment of free magnesium concentration in human brain by 31P MRS. A new calibration curve based on a mathematical algorithm. NMR Biomed 9, 24-32 (1996). 220. Iotti, S., Frassineti, C., Sabatini, A., Vacca, A. & Barbiroli, B. Quantitative mathematical expressions for accurate in vivo assessment of cytosolic [ADP] and DeltaG of ATP hydrolysis in the human brain and skeletal muscle. Biochim Biophys Acta 1708, 164-177 (2005). 221. Barbiroli, B., et al. Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 13, 469-474 (1993). 222. Minati, L., Aquino, D., Bruzzone, M.G. & Erbetta, A. Quantitation of normal metabolite concentrations in six brain regions by in-vivoH-MR spectroscopy. J Med Phys 35, 154-163 (2010). 223. Hangel, G., et al. Inter-subject stability and regional concentration estimates of 3D-FID-MRSI in the human brain at 7 T. NMR in Biomedicine 34, e4596 (2021). 224. Tal, A., Kirov, II, Grossman, R.I. & Gonen, O. The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed 25, 1392-1400 (2012). 225. Wright, I.C., et al. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage 2, 244-252 (1995). 226. Sarafian, M.H., et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem 87, 9662-9670 (2015). 227. Bertoni-Freddari, C., et al. Role of Mitochondrial Deterioration in Physiological and Pathological Brain Aging. Gerontology 50, 187-192 (2004). 228. Forester, B.P., et al. Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed 23, 242-250 (2010). 229. Folstein, M.F., Folstein, S.E. & McHugh, P.R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198 (1975). 230. Creavin, S.T., et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev, CD011145 (2016). 231. Allen, S.P., et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiology of Aging 35, 1499-1509 (2014). 232. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 57, 289-300 (1995). 233. Evans, L.D. A two-score composite program for combining standard scores. Behavior Research Methods, Instruments, & Computers 28, 209-213 (1996). 234. Yang, W., et al. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis 6, 15 (2020). 235. Borsche, M., Pereira, S.L., Klein, C. & Grunewald, A. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis 11, 45-60 (2021). 236. Zambrano, K., et al. Fighting Parkinson's disease: The return of the mitochondria. Mitochondrion 64, 34-44 (2022). 237. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14, 795-803 (2015). 238. Cuevas, E., et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease. Nutr Neurosci, 1-18 (2020). 239. Rosa, A.I., et al. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease. Mol Neurobiol 55, 9139-9155 (2018). 240. Moreira, S., et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. Exp Neurol 295, 77-87 (2017). 241. Goulis, J., Leandro, G. & Burroughs, A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354, 1053-1060 (1999). 242. Cole, M.H., Silburn, P.A., Wood, J.M., Worringham, C.J. & Kerr, G.K. Falls in Parkinson's disease: kinematic evidence for impaired head and trunk control. Mov Disord 25, 2369-2378 (2010). 243. Hubble, R.P., Naughton, G.A., Silburn, P.A. & Cole, M.H. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review. PLoS One 10, e0123705 (2015). 244. Payne, T., et al. Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open 10, e038911 (2020). 245. Nasreddine, Z.S., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53, 695-699 (2005). 246. Montgomery, S.A. & Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134, 382-389 (1979). 247. Chaudhuri, K.R., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21, 916-923 (2006). 248. Richards, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17, 405-424 (2015). 249. Wolfer, A.M., et al. peakPantheR, an R package for large-scale targeted extraction and integration of annotated metabolic features in LC-MS profiling datasets. Bioinformatics 37, 4886-4888 (2021). 250. Trojaniello, D., Ravaschio, A., Hausdorff, J.M. & Cereatti, A. Comparative assessment of different methods for the estimation of gait temporal parameters using a single inertial sensor: application to elderly, post-stroke, Parkinson's disease and Huntington's disease subjects. Gait Posture 42, 310-316 (2015). 251. Spain, R.I., et al. Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture 35, 573-578 (2012). 252. Moe-Nilssen, R. & Helbostad, J.L. Estimation of gait cycle characteristics by trunk accelerometry. J Biomech 37, 121-126 (2004). 253. Galna, B., Lord, S. & Rochester, L. Is gait variability reliable in older adults and Parkinson's disease? Towards an optimal testing protocol. Gait Posture 37, 580-585 (2013). 254. Moe-Nilssen, R. A new method for evaluating motor control in gait under real-life environmental conditions. Part 1: The instrument. Clin Biomech 13, 320-327 (1998). 255. Angelini, L., et al. Is a Wearable Sensor-Based Characterisation of Gait Robust Enough to Overcome Differences Between Measurement Protocols? A Multi-Centric Pragmatic Study in Patients with Multiple Sclerosis. Sensors 20, 79 (2019). 256. Salarian, A., et al. Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. IEEE Trans Biomed Eng 51, 1434-1443 (2004). 257. Ordidge, R.J., Connelly, A. & Lohman, J.A.B. Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy. J Magn Reson 66, 283-294 (1986). 258. Ordidge, R.J., Bowley, R.M. & McHale, G. A general approach to selection of multiple cubic volume elements using the ISIS technique. Magn Reson Med 8, 323-331 (1988). 259. Stefan, D., et al. Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package. Meas Sci Technol 20(2009). 260. de Graaf, R.A. Spectral Quantification. in In Vivo NMR Spectroscopy 439-471 (John Wiley & Sons, Ltd., 2019). 261. Iotti, S. & Malucelli, E. In vivo assessment of Mg2+ in human brain and skeletal muscle by 31P-MRS. Magnes Res 21, 157-162 (2008). 262. Schmitz, B., et al. Effects of Aging on the Human Brain: A Proton and Phosphorus MR Spectroscopy Study at 3T. J Neuroimaging 28, 416-421 (2018). 263. Athauda, D., et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664-1675 (2017). 264. Goetz, C.G., et al. Handling missing values in the MDS-UPDRS. Mov Disord 30, 1632-1638 (2015). 265. Ward, A., Brogden, R.N., Heel, R.C., Speight, T.M. & Avery, G.S. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 27, 95-131 (1984). 266. Simuni, T., et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 78, 312-320 (2021). 267. Pagan, F.L., et al. Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol 77, 309-317 (2020). 268. Vaz, A.R., et al. Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid. J Neurochem 112, 56-65 (2010). 269. Brito, M.A., et al. Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology 29, 259-269 (2008). 270. Li, H., et al. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 12, 788558 (2021). 271. Tang, R., et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67, 534-541 (2018). 272. Whone, A., et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain 142, 512-525 (2019). 273. Kieburtz, K., Katz, R., McGarry, A. & Olanow, C.W. A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic. Mov Disord 36, 59-63 (2021). 274. Mico-Amigo, M.E., et al. Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. Front Hum Neurosci 13, 59 (2019). 275. Hobert, M.A., et al. Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. Front Aging Neurosci 11, 22 (2019). 276. Amboni, M., et al. Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. J Neurol 265, 2211-2220 (2018). 277. Galna, B., Lord, S., Burn, D.J. & Rochester, L. Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov Disord 30, 359-367 (2015). 278. van der Heide, A., Meinders, M.J., Bloem, B.R. & Helmich, R.C. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson's Disease. J Parkinsons Dis 10, 1355-1364 (2020). 279. Pissadaki, E.K. & Bolam, J.P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci 7, 13 (2013). 280. Mullin, S., et al. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol 77, 427-434 (2020). 281. Chong, R., et al. Niacin Enhancement for Parkinson's Disease: An Effectiveness Trial. Front Aging Neurosci 13, 667032 (2021). 282. Patel, D. & Witt, S.N. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. Oxid Med Cell Longev 2017, 4829180 (2017). 283. Osman, C., Voelker, D.R. & Langer, T. Making heads or tails of phospholipids in mitochondria. J Cell Biol 192, 7-16 (2011). 284. Riekkinen, P., Rinne, U.K., Pelliniemi, T.-T. & Sonninen, V. Interaction Between Dopamine and Phospholipids: Studies of the Substantia Nigra in Parkinson Disease Patients. Archives of Neurology 32, 25-27 (1975). 285. Chang, K.-H., et al. Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson's Disease. Cells 11, 395 (2022). 286. Manyam, B.V., Ferraro, T.N. & Hare, T.A. Cerebrospinal Fluid Amino Compounds in Parkinson's Disease: Alterations due to Carbidopa/Levodopa. Archives of Neurology 45, 48-50 (1988). 287. Brockmann, K., et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 79, 213-220 (2012). 288. Bell, S.M., et al. Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future? Biomedicines 9(2021). 289. Shi, X.-F., et al. Decreased brain PME/PDE ratio in bipolar disorder: a preliminary 31P magnetic resonance spectroscopy study. Bipolar Disorders 17, 743-752 (2015). 290. Haszto, C.S., Stanley, J.A., Iyengar, S. & Prasad, K.M. Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies. Biol Psychiatry Cogn Neurosci Neuroimaging 5, 264-280 (2020). 291. Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H.R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson's disease. The Lancet Neurology 20, 559-572 (2021). 292. Parker, W.D., Jr., Parks, J.K. & Swerdlow, R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189, 215-218 (2008). 293. Murphy, K.E., et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137, 834-848 (2014). 294. Rakovic, A., et al. Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 6, e16746 (2011). 295. Iles, R.A., Stevens, A.N., Griffiths, J.R. & Morris, P.G. Phosphorylation status of liver by 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n.m.r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 229, 141-151 (1985). 296. Meyerspeer, M., et al. 31P magnetic resonance spectroscopy in skeletal muscle: Experts' consensus recommendations. NMR in Biomedicine 34, e4246 (2021). 297. Lesage, S., et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73, 459-471 (2013). 298. Pankratz, N., et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 73, 279-286 (2009). 299. Lyamzaev, K.G., et al. Induction of autophagy by depolarization of mitochondria. Autophagy 14, 921-924 (2018). 300. Ivankovic, D., Chau, K.Y., Schapira, A.H. & Gegg, M.E. Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J Neurochem 136, 388-402 (2016). 301. Andres, R.H., Ducray, A.D., Schlattner, U., Wallimann, T. & Widmer, H.R. Functions and effects of creatine in the central nervous system. Brain Res Bull 76, 329-343 (2008). 302. Das, N., Ren, J., Spence, J.S., Rackley, A. & Chapman, S.B. Relationship of Parieto-Occipital Brain Energy Phosphate Metabolism and Cognition Using (31)P MRS at 7-Tesla in Amnestic Mild Cognitive Impairment. Frontiers in aging neuroscience 12, 222-222 (2020). 303. von Bartheld, C.S., Bahney, J. & Herculano-Houzel, S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. J Comp Neurol 524, 3865-3895 (2016). 304. Yakhine-Diop, S.M.S., et al. Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson's Disease Patients. Mol Neurobiol 56, 2466-2481 (2019). 305. Matsuda, N., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189, 211-221 (2010). 306. Diano, S., et al. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 144, 5014-5021 (2003). 307. Bloem, B.R., Okun, M.S. & Klein, C. Parkinson's disease. The Lancet 397, 2284-2303 (2021). 308. Grunewald, A., Kumar, K.R. & Sue, C.M. New insights into the complex role of mitochondria in Parkinson's disease. Prog Neurobiol 177, 73-93 (2019). 309. Payne, T., et al. 31Phosphorus magnetic resonance spectroscopy in Parkinson’s disease demonstrates relationships with predicted disease progression and mitochondrial dysfunction in the peripheral tissue. (Mansucript in preparation for submission to Annals of Neurology, 2022). 310. van der Heeden, J.F., et al. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 86, 2243 (2016). 311. Lawson, R.A., et al. Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. Journal of Parkinson's disease 11, 1297-1308 (2021). 312. Williams-Gray, C.H., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132, 2958-2969 (2009). 313. Haszto, C.S., Stanley, J.A., Iyengar, S. & Prasad, K.M. Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies. Biol Psychiatry Cogn Neurosci Neuroimaging 5, 264-280 (2020). 314. Combs, H.L., Wyman-Chick, K.A., Erickson, L.O. & York, M.K. Development of standardized regression-based formulas to assess meaningful cognitive change in early Parkinson’s disease. Archives of Clinical Neuropsychology 36, 734-745 (2021). 315. Eickhoff, C.R., et al. Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. Brain Commun 3, fcab191-fcab191 (2021). 316. Ward, C.D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57, 217-220 (1994). 317. Group, T.P.S. Cerebrospinal Fluid Homovanillic Acid in the DATATOP Study on Parkinson's Disease. Archives of Neurology 52, 237-245 (1995). 318. Simon, D.K., et al. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis 5, 731-736 (2015). 319. de Lau, L.M., Koudstaal, P.J., Hofman, A. & Breteler, M.M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58, 797-800 (2005). 320. Athauda, D., et al. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol 76, 420-429 (2019). 321. Horvath, K., et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord 21, 1421-1426 (2015). 322. Carroll, C.B., et al. Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study. BMJ Open 9, e029740 (2019). 323. Mazzà, C., et al. Technical validation of real-world monitoring of gait: a multicentric observational study. BMJ open 11, e050785-e050785 (2021). 324. Kimmeskamp, S. & Hennig, E.M. Heel to toe motion characteristics in Parkinson patients during free walking. Clinical Biomechanics 16, 806-812 (2001). 325. Raffegeau, T.E., et al. A meta-analysis: Parkinson's disease and dual-task walking. 326. Del Din, S., Godfrey, A., Mazzà, C., Lord, S. & Rochester, L. Free-living monitoring of Parkinson's disease: Lessons from the field. Movement Disorders 31, 1293-1313 (2016). 327. Lo, C., et al. A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease. Journal of Neurology, Neurosurgery &amp; Psychiatry 93, 617 (2022). 328. Wu, C.A.-O., et al. Responsiveness, Minimal Clinically Important Difference, and Validity of the MoCA in Stroke Rehabilitation. 329. Skorvanek, M., et al. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. 330. Rittman, T., et al. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. 331. Lucza, T.A.-O.X., et al. Comparing Sensitivity and Specificity of Addenbrooke's Cognitive Examination-I, III and Mini-Addenbrooke's Cognitive Examination in Parkinson's Disease. 332. Vijiaratnam, N.A.-O., et al. Combining biomarkers for prognostic modelling of Parkinson's disease. 333. Greenland, J.C., Williams-Gray, C.H. & Barker, R.A. The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci (2018). 334. Espay, A.J., et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord 32, 319-324 (2017). 335. Bingol, B., et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510, 370-375 (2014). 336. Pettegrew, J.W., Panchalingam, K., Klunk, W.E., McClure, R.J. & Muenz, L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 15, 117-132 (1994). 337. Ross, A.J. & Sachdev, P.S. Magnetic resonance spectroscopy in cognitive research. Brain Research Reviews 44, 83-102 (2004). 338. Pavese, N. & Tai, Y.F. Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. Movement disorders clinical practice 5, 131-140 (2018). 339. Cuenoud, B., et al. Brain NAD Is Associated With ATP Energy Production and Membrane Phospholipid Turnover in Humans. Frontiers in aging neuroscience 12, 609517-609517 (2020). 340. Deus, C.M., et al. Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects. Biochim Biophys Acta Mol Basis Dis 1866, 165615 (2020). 341. Lapasset, L., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 25, 2248-2253 (2011). 342. Chang, C.-K., et al. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo (1)H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome. Diagnostics (Basel) 11, 1541 (2021)."]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Ph.D"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://etheses.whiterose.ac.uk/id/eprint/31442/1/Thesis%20Final%20Corrected.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Mitochondrial dysfunction as a therapeutic target in Parkinson's Disease"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bandmann, Oliver","Jenkins, Thomas","Mortiboys, Heather"],"dc:contributor.sponsor":["Cure Parkinson's Trust","Michael J Fox Foundation","The Jon Moulton Charity Trust"],"dc:creator":["Payne, Thomas"],"dc:date":["2022-04"],"dc:date.issued":["2022-04"],"dc:format":["text"],"dc:identifier.uri":["https://etheses.whiterose.ac.uk/id/eprint/31442/1/Thesis%20Final%20Corrected.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["Medicine (Sheffield)"],"dc:publisher.institution":["University of Sheffield"],"dc:relation.isreferencedby":["https://etheses.whiterose.ac.uk/id/eprint/31442/"],"dc:relation.references":["1. Dorsey, E.R., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384-386 (2007). 2. Kalia, L.V. & Lang, A.E. Parkinson's disease. The Lancet 386, 896-912 (2015). 3. Findley, L.J., et al. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 14, 130-139 (2011). 4. Lees, A. An essay on the shaking palsy. Brain 140, 843-848 (2017). 5. Schapira, A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54, 823-827 (1990). 6. van der Brug, M.P., Singleton, A., Gasser, T. & Lewis, P.A. Parkinson's disease: From human genetics to clinical trials. Sci Transl Med 7, 205ps220 (2015). 7. Schapira, A.H., Olanow, C.W., Greenamyre, J.T. & Bezard, E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384, 545-555 (2014). 8. Pringsheim, T., Jette, N., Frolkis, A. & Steeves, T.D. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29, 1583-1590 (2014). 9. Collaborators, G.B.D.P.s.D. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17, 939-953 (2018). 10. Heinzel, S., et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 34, 1464-1470 (2019). 11. Berg, D., et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 30, 1600-1611 (2015). 12. Gibb, W.R. & Lees, A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51, 745-752 (1988). 13. Hughes, A.J., Daniel, S.E., Kilford, L. & Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184 (1992). 14. Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y. & Lees, A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861-870 (2002). 15. Wojtala, J., et al. Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. J Neurol Neurosurg Psychiatry 90, 171-179 (2019). 16. Post, B., Merkus, M.P., de Haan, R.J., Speelman, J.D. & Group, C.S. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 22, 1839-1851; quiz 1988 (2007). 17. Velseboer, D.C., et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 86, 986-993 (2016). 18. Mancini, M., et al. Trunk accelerometry reveals postural instability in untreated Parkinson's disease. Parkinsonism Relat Disord 17, 557-562 (2011). 19. Knudsen, K., Krogh, K., Ostergaard, K. & Borghammer, P. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Mov Disord 32, 94-105 (2017). 20. Adams-Carr, K.L., et al. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 87, 710-716 (2016). 21. Zhang, J., Xu, C.Y. & Liu, J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. BMC Neurol 17, 23 (2017). 22. Postuma, R.B., et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 142, 744-759 (2019). 23. Zis, P., Erro, R., Walton, C.C., Sauerbier, A. & Chaudhuri, K.R. The range and nature of non-motor symptoms in drug-naive Parkinson's disease patients: a state-of-the-art systematic review. NPJ Parkinsons Dis 1, 15013 (2015). 24. Riedel, O., et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. Journal of Neurology 257, 1073-1082 (2010). 25. Wood, R.A., Hopkins, S.A., Moodley, K.K. & Chan, D. Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients. Front Neurol 6, 263 (2015). 26. Goetz, C.G., Stebbins, G.T. & Ouyang, B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord 26, 2196-2200 (2011). 27. Factor, S.A., et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. Journal of the neurological sciences 347, 316-321 (2014). 28. Broeders, M., et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology 81, 346-352 (2013). 29. Hobson, P. & Meara, J. Mild cognitive impairment in Parkinson's disease and its progression onto dementia: a 16-year outcome evaluation of the Denbighshire cohort. International Journal of Geriatric Psychiatry 30, 1048-1055 (2015). 30. Aarsland, D., Zaccai, J. & Brayne, C. A systematic review of prevalence studies of dementia in Parkinson's disease. Movement Disorders 20, 1255-1263 (2005). 31. Galtier, I., Nieto, A., Lorenzo, J.N. & Barroso, J. Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study. J Neurol 266, 745-754 (2019). 32. Vossius, C., Larsen, J.P., Janvin, C. & Aarsland, D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 26, 1541-1544 (2011). 33. Macleod, A.D., Taylor, K.S. & Counsell, C.E. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 29, 1615-1622 (2014). 34. Dommershuijsen, L.J., et al. Life expectancy of parkinsonism patients in the general population. Parkinsonism Relat Disord 77, 94-99 (2020). 35. LeWitt, P.A. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30, 64-72 (2015). 36. Group, T.P.S. Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine 351, 2498-2508 (2004). 37. Verschuur, C.V.M., et al. Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease. New England Journal of Medicine 380, 315-324 (2019). 38. Rossi, C., Del Prete, E. & Bonuccelli, U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease AU - Ceravolo, Roberto. Expert Opinion on Drug Safety 15, 181-198 (2016). 39. Kordower, J.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419-2431 (2013). 40. Braak, H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211 (2003). 41. Lautenschlager, J., et al. C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun 9, 712 (2018). 42. Diao, J., et al. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2, e00592 (2013). 43. Man, W.K., et al. The docking of synaptic vesicles on the presynaptic membrane induced by alpha-synuclein is modulated by lipid composition. Nat Commun 12, 927 (2021). 44. Parkkinen, L., Kauppinen, T., Pirttila, T., Autere, J.M. & Alafuzoff, I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57, 82-91 (2005). 45. Klos, K.J., et al. α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66, 1100-1102 (2006). 46. Polymeropoulos, M.H., et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease. Science 276, 2045-2047 (1997). 47. Book, A., et al. A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism. Frontiers in Neurology 9(2018). 48. Trinh, J., et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 33, 1857-1870 (2018). 49. Kalia, L.V., et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72, 100-105 (2015). 50. Sidransky, E., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361, 1651-1661 (2009). 51. Winder-Rhodes, S.E., et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136, 392-399 (2013). 52. Gegg, M.E., et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 72, 455-463 (2012). 53. Friedman, J.R. & Nunnari, J. Mitochondrial form and function. Nature 505, 335-343 (2014). 54. Chaban, Y., Boekema, E.J. & Dudkina, N.V. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim Biophys Acta 1837, 418-426 (2014). 55. Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L. & Neuzil, J. Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta 1827, 552-564 (2013). 56. Kadenbach, B. Complex IV - The regulatory center of mitochondrial oxidative phosphorylation. Mitochondrion 58, 296-302 (2021). 57. Chen, G., Kroemer, G. & Kepp, O. Mitophagy: An Emerging Role in Aging and Age-Associated Diseases. Front Cell Dev Biol 8, 200 (2020). 58. Eisner, V., Picard, M. & Hajnoczky, G. Mitochondrial dynamics in adaptive and maladaptive cellular stress responses. Nat Cell Biol 20, 755-765 (2018). 59. Kleele, T., et al. Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature 593, 435-439 (2021). 60. Langston, J., Ballard, P., Tetrud, J. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983). 61. Chiueh, C.C., et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 20, 548-553 (1984). 62. Nguyen, T.N., Padman, B.S. & Lazarou, M. Deciphering the Molecular Signals of PINK1/Parkin Mitophagy. Trends in Cell Biology 26, 733-744 (2016). 63. Su, Y.C. & Qi, X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet. 15, 4545-4561 (2013). 64. Mortiboys, H., Johansen, K.K., Aasly, J.O. & Bandmann, O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75, 2017-2020 (2010). 65. Girotto, S., et al. Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53. J Biol Chem 287, 18738-18749 (2012). 66. Toulorge, D., Schapira, A.H. & Hajj, R. Molecular changes in the postmortem parkinsonian brain. J Neurochem 139 Suppl 1, 27-58 (2016). 67. Wang, X., et al. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathologica Communications 7, 41 (2019). 68. Shahmoradian, S.H., et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nature Neuroscience 22, 1099-1109 (2019). 69. Sian, J., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36, 348-355 (1994). 70. Zhang, J., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. The American journal of pathology 154, 1423-1429 (1999). 71. Coxhead, J., et al. Somatic mtDNA variation is an important component of Parkinson's disease. Neurobiol Aging 38, 217 e211-217 e216 (2016). 72. Pyle, A., et al. Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. Neurobiol Aging 38, 216 e217-216 e210 (2016). 73. Schwartzentruber, A., et al. Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons. Sci Rep 10, 15485 (2020). 74. Hou, X., et al. Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy 14, 1404-1418 (2018). 75. Hruska, K.S., LaMarca, M.E., Scott, C.R. & Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29, 567-583 (2008). 76. Mazzulli, J.R., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37-52 (2011). 77. McNeill, A., et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481-1495 (2014). 78. Goker-Alpan, O., Stubblefield, B.K., Giasson, B.I. & Sidransky, E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120, 641-649 (2010). 79. Anderson, J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281, 29739-29752 (2006). 80. Sanjeev, A. & Mattaparthi, V.S.K. Computational investigation on the effects of H50Q and G51D mutations on the α-Synuclein aggregation propensity. Journal of Biomolecular Structure and Dynamics 36, 2224-2236 (2018). 81. Hayakawa, H., et al. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology. Movement disorders : official journal of the Movement Disorder Society 35, 256-267 (2020). 82. Lashuel, H.A., et al. α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal of Molecular Biology 322, 1089-1102 (2002). 83. Li, J.-Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 14, 501-503 (2008). 84. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B. & Olanow, C.W. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 14, 504-506 (2008). 85. Desplats, P., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 106, 13010-13015 (2009). 86. Masuda-Suzukake, M., et al. Prion-like spreading of pathological α-synuclein in brain. Brain : a journal of neurology 136, 1128-1138 (2013). 87. Hilton, D., et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathologica 127, 235-241 (2014). 88. Stokholm, M.G., Danielsen, E.H., Hamilton-Dutoit, S.J. & Borghammer, P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Annals of Neurology 79, 940-949 (2016). 89. Van Den Berge, N., et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 138, 535-550 (2019). 90. Kim, S., et al. Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron 103, 627-641 e627 (2019). 91. Gao, X., Chen H Fau - Schwarzschild, M.A., Schwarzschild Ma Fau - Ascherio, A. & Ascherio, A. Use of ibuprofen and risk of Parkinson disease. Neurology 76, 863-869 (2011). 92. Racette, B.A., et al. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol 5, 870-875 (2018). 93. McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291 (1988). 94. Gerhard, A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of disease 21, 404-412 (2006). 95. Williams-Gray, C.H., et al. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Mov Disord 31, 995-1003 (2016). 96. Greenland, J.C., et al. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open 10, e040527 (2020). 97. Marras, C., Lang, A.E., Austin, P.C., Lau, C. & Urbach, D.R. Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. Mov Disord 31, 1243-1247 (2016). 98. Kim, R., Lee, J.Y., Park, S., Han, K. & Shin, C.M. Cholecystectomy and subsequent risk of Parkinson's disease: a nationwide retrospective cohort study. NPJ Parkinsons Dis 7, 100 (2021). 99. Malagelada, J.R., Go, V.L.W., Summerskill, W.H.J. & Gamble, W.S. Bile acid secretion and biliary bile acid composition altered by cholecystectomy. The American Journal of Digestive Diseases 18, 455-459 (1973). 100. Hepner, G.W., Hofmann, A.F., Malagelada, J.R., Szczepanik, P.A. & Klein, P.D. Increased Bacterial Degradation of Bile Acids in Cholecystectomized Patients. Gastroenterology 66, 556-564 (1974). 101. Kullak-Ublick, G.-A., Paumgartner, G. & Berr, F. Long-term effects of cholecystectomy on bile acid metabolism. Hepatology 21, 41-45 (1995). 102. Chen, M.L., Takeda, K. & Sundrud, M.S. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunology 12, 851-861 (2019). 103. Pavlidis, P., et al. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Alimentary Pharmacology & Therapeutics 42, 802-817 (2015). 104. Grant, S.M. & DeMorrow, S. Bile Acid Signaling in Neurodegenerative and Neurological Disorders. Int J Mol Sci 21, 5982 (2020). 105. Huang, F., et al. Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior. Front Behav Neurosci 9, 70-70 (2015). 106. McMillin, M., et al. TGR5 signaling reduces neuroinflammation during hepatic encephalopathy. Journal of neurochemistry 135, 565-576 (2015). 107. McMillin, M., et al. Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice. Frontiers in cellular neuroscience 11, 191-191 (2017). 108. Romano, S., et al. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 7, 27 (2021). 109. Li, P., et al. Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. Metabolites 11(2021). 110. Shao, Y., et al. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Mol Neurodegener 16, 4 (2021). 111. Graham, S.F., et al. Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson's Disease. Metabolites 8(2018). 112. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46, 1052-1060 (1989). 113. Snow, B.J., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25, 1670-1674 (2010). 114. The Parkinson Study Group QE3 Investigators, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71, 543-552 (2014). 115. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313, 584-593 (2015). 116. The Parkinson Study Group SURE-PD3 Investigators, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA 326, 926-939 (2021). 117. Jankovic, J., et al. Variable expression of Parkinson's disease. A base‐line analysis of the DAT ATOP cohort 40, 1529-1529 (1990). 118. Stebbins, G.T., et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 28, 668-670 (2013). 119. Alves, G., Larsen, J.P., Emre, M., Wentzel-Larsen, T. & Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Movement Disorders 21, 1123-1130 (2006). 120. Simuni, T., et al. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 28, 62-67 (2016). 121. Aleksovski, D., Miljkovic, D., Bravi, D. & Antonini, A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39, 1971-1976 (2018). 122. Goetz, C.G., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23, 2129-2170 (2008). 123. Post, B., Merkus, M.P., de Bie, R.M., de Haan, R.J. & Speelman, J.D. Unified Parkinson's disease rating scale motor examination: are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? Mov Disord 20, 1577-1584 (2005). 124. Chaudhuri, K.R., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 22, 1901-1911 (2007). 125. Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age and ageing 26, 353-357 (1997). 126. Del Din, S., et al. Gait analysis with wearables predicts conversion to parkinson disease. Ann Neurol 86, 357-367 (2019). 127. Buckley, C., Galna, B., Rochester, L. & Mazzà, C. Upper body accelerations as a biomarker of gait impairment in the early stages of Parkinson’s disease. Gait & Posture 71, 289-295 (2019). 128. Rehman, R.Z.U., et al. Accelerometry-Based Digital Gait Characteristics for Classification of Parkinson's Disease: What Counts? IEEE Open Journal of Engineering in Medicine and Biology 1, 65-73 (2020). 129. Wilson, J., et al. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 36, 611-621 (2021). 130. Wilson, J., et al. Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology. Frontiers in Aging Neuroscience 12(2020). 131. Kluge, A.F., et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorganic & Medicinal Chemistry Letters 28, 2655-2659 (2018). 132. Prasuhn, J., et al. An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol Res Pract 1, 31 (2019). 133. Gmitterova, K., et al. 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases. Neuro-degenerative diseases 6, 263-269 (2009). 134. Abe, T., Isobe, C., Murata, T., Sato, C. & Tohgi, H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 336, 105-108 (2003). 135. Mortiboys, H., et al. Translational approaches to restoring mitochondrial function in Parkinson's disease. FEBS Lett 592, 776-792 (2018). 136. Lewitt, P.A., et al. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord 28, 1653-1660 (2013). 137. Konings, C.H., et al. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. Journal of the neurological sciences 168, 112-115 (1999). 138. Waragai, M., et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochemical and biophysical research communications 345, 967-972 (2006). 139. Herbert, M.K., et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20, 112-115 (2014). 140. Hong, Z., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726 (2010). 141. Shi, M., et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480, 78-82 (2010). 142. Waragai, M., et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425, 18-22 (2007). 143. Maita, C., et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431, 86-89 (2008). 144. Chen, C.M., et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiology of disease 33, 429-435 (2009). 145. Shukla, R., Rajani, M., Srivastava, N., Barthwal, M.K. & Dikshit, M. Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. The International journal of neuroscience 116, 1391-1402 (2006). 146. Burte, F., et al. metabolic profiling of Parkinson's disease and mild cognitive impairment. Mov Disord 32, 927-932 (2017). 147. Pyle, A., et al. Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. Ann Neurol 78, 1000-1004 (2015). 148. Podlesniy, P., et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology 74, 655-668 (2013). 149. Podlesniy, P., et al. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiology of disease 94, 10-17 (2016). 150. Davis, R.L., et al. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 81, 1819-1826 (2013). 151. Davis, R.L., Liang, C. & Sue, C.M. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology 86, 2010-2015 (2016). 152. Yao, X., et al. Serum Growth Differentiation Factor 15 in Parkinson Disease. Neuro-degenerative diseases 17, 251-260 (2017). 153. Davis, R.L., et al. Serum FGF-21, GDF-15, and blood mtDNA copy number are not biomarkers of Parkinson disease. Neurol Clin Pract 10, 40-46 (2020). 154. Shen, C., Guo, Y., Luo, W., Lin, C. & Ding, M. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 40, 73-79 (2013). 155. Gao, X., O'Reilly, É.J., Schwarzschild, M.A. & Ascherio, A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86, 520-526 (2016). 156. Ascherio, A., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66, 1460-1468 (2009). 157. Koros, C., et al. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism & Related Disorders 84, 1-4 (2021). 158. Koros, C., et al. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson’s Disease: Data from the PPMI Study. Journal of Parkinson's Disease 10, 481-487 (2020). 159. Mortiboys, H., et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 64, 555-565 (2008). 160. Auburger, G., et al. Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol 46, 20-27 (2012). 161. Carling, P.J., et al. Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson's disease. Prog Neurobiol 187, 101772 (2020). 162. Meyer, K., et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc Natl Acad Sci U S A 111, 829-832 (2014). 163. Mertens, J., et al. Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. Cell Stem Cell 17, 705-718 (2015). 164. Milanese, C., et al. Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease. Mov Disord 34, 1192-1202 (2019). 165. de Graaf, R.A. Basic Principles. in In Vivo NMR Spectroscopy 1-42 (John Wiley & Sons, Ltd., 2019). 166. de Graaf, R.A. In Vivo NMR Spectroscopy – Static Aspects. in In Vivo NMR Spectroscopy 43-128 (John Wiley & Sons, Ltd., 2019). 167. de Graaf, R.A. In Vivo NMR Spectroscopy – Dynamic Aspects. in In Vivo NMR Spectroscopy 129-210 (John Wiley & Sons, Ltd., 2019). 168. de Graaf, R.A. Magnetic Resonance Imaging. in In Vivo NMR Spectroscopy 211-252 (John Wiley & Sons, Ltd., 2019). 169. de Graaf, R.A. Radiofrequency Pulses. in In Vivo NMR Spectroscopy 253-291 (John Wiley & Sons, Ltd., 2019). 170. de Graaf, R.A. Spectroscopic Imaging and Multivolume Localization. in In Vivo NMR Spectroscopy 335-373 (John Wiley & Sons, Ltd., 2019). 171. Boer, V.O. & Klomp, D.W.J. Chapter 1.3 - Technical Considerations for Multivoxel Approaches and Magnetic Resonance Spectroscopic Imaging. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 31-39 (Academic Press, San Diego, 2014). 172. de Graaf, R.A. Chapter 1.4 - Spectral Editing and 2D NMR. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 40-48 (Academic Press, San Diego, 2014). 173. Juchem, C. & Rothman, D.L. Chapter 1.1 - Basis of Magnetic Resonance. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 3-14 (Academic Press, San Diego, 2014). 174. Lei, H., Xin, L., Gruetter, R. & Mlynárik, V. Chapter 1.2 - Localized Single-Voxel Magnetic Resonance Spectroscopy, Water Suppression, and Novel Approaches for Ultrashort Echo-Time Measurements. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 15-30 (Academic Press, San Diego, 2014). 175. Near, J. Chapter 1.5 - Spectral Quantification and Pitfalls in Interpreting Magnetic Resonance Spectroscopic Data: What To Look Out For. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 49-67 (Academic Press, San Diego, 2014). 176. Thulborn, K.R. & Atkinson, I.C. Chapter 4.1 - Quantitative Metabolic Magnetic Resonance Imaging of Sodium, Oxygen, Phosphorus and Potassium in the Human Brain: A Rationale for Bioscales in Clinical Applications. in Magnetic Resonance Spectroscopy (eds. Stagg, C. & Rothman, D.) 291-311 (Academic Press, San Diego, 2014). 177. Blüml, S. Magnetic Resonance Spectroscopy: Basics. in MR Spectroscopy of Pediatric Brain Disorders 11-23 (2013). 178. Weinberg, B.D., Kuruva, M., Shim, H. & Mullins, M.E. Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment. Radiol Clin North Am 59, 349-362 (2021). 179. Rijpma, A., van der Graaf, M., Meulenbroek, O., Olde Rikkert, M.G.M. & Heerschap, A. Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional (31)P MR spectroscopic imaging study. NeuroImage. Clinical 18, 254-261 (2018). 180. Sassani, M., et al. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain 143, 3603-3618 (2020). 181. Hu, M.T.M., et al. Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31P-MRS and 18FDG-PET study. Brain 123, 340-352 (2000). 182. Provencher, S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14, 260-264 (2001). 183. Vanhamme, L., van den Boogaart, A. & Van Huffel, S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129, 35-43 (1997). 184. Barbiroli, B., Iotti, S. & Lodi, R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 9, 253-260 (1999). 185. Barbiroli, B., et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 14, 430-435 (1999). 186. Belanger, M., Allaman, I. & Magistretti, P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14, 724-738 (2011). 187. Rango, M., Bonifati, C. & Bresolin, N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26, 283-290 (2006). 188. Rango, M., Dossi, G., Squarcina, L. & Bonifati, C. Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation. Mov Disord 35, 504-507 (2020). 189. Hattingen, E., et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132, 3285-3297 (2009). 190. Bottomley, P.A. & Hardy, C.J. Rapid, reliable in vivo assays of human phosphate metabolites by nuclear magnetic resonance. Clin Chem 35, 392-395 (1989). 191. Hilker, R., et al. The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations. PLoS One 7, e51308 (2012). 192. Weiduschat, N., et al. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 25, 105-110 (2015). 193. Weiduschat, N., et al. Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism Relat Disord 20, 545-548 (2014). 194. Cai, R., et al. Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. J Clin Invest 129, 4539-4549 (2019). 195. Schultz, J.L., et al. A pilot to assess target engagement of terazosin in Parkinson's disease. Parkinsonism Relat Disord 94, 79-83 (2022). 196. Sathe, A.G., et al. Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease-A Pilot Study. J Clin Pharmacol 60, 744-750 (2020). 197. Lei, H., Ugurbil, K. & Chen, W. Measurement of unidirectional Pi to ATP flux in human visual cortex at 7 T by using in vivo 31P magnetic resonance spectroscopy. Proceedings of the National Academy of Sciences of the United States of America 100, 14409-14414 (2003). 198. Nabuurs, C., Huijbregts, B., Wieringa, B., Hilbers, C.W. & Heerschap, A. 31P saturation transfer spectroscopy predicts differential intracellular macromolecular association of ATP and ADP in skeletal muscle. The Journal of biological chemistry 285, 39588-39596 (2010). 199. Peng, J., Liu, Q., Rao, M.S. & Zeng, X. Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen 18, 522-533 (2013). 200. Mortiboys, H., Aasly, J. & Bandmann, O. Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain 136, 3038-3050 (2013). 201. Mortiboys, H., et al. UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85, 846-852 (2015). 202. Chun, H.S. & Low, W.C. Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology 292, 105-112 (2012). 203. Abdelkader, N.F., Safar, M.M. & Salem, H.A. Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. Mol Neurobiol 53, 810-817 (2016). 204. Castro-Caldas, M., et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol 46, 475-486 (2012). 205. Greene, L.A., Levy, O. & Malagelada, C. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol 31, 969-978 (2011). 206. Abbas, G. & Lindor, K.D. Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert opinion on pharmacotherapy 11, 387-392 (2010). 207. Lazaridis, K.N., Gores, G.J. & Lindor, K.D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 35, 134-146 (2001). 208. Bell, S.M., et al. Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's Disease. J Mol Biol 430, 3942-3953 (2018). 209. Parry, G.J., et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clinical neuropharmacology 33, 17-21 (2010). 210. Kim, H.M., et al. Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. Clin Park Relat Disord 1, 91-97 (2019). 211. Tomlinson, C.L., et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25, 2649-2653 (2010). 212. Holden, S.K., Finseth, T., Sillau, S.H. & Berman, B.D. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort. Mov Disord Clin Pract 5, 47-53 (2018). 213. Hoehn, M.M. & Yahr, M.D. Parkinsonism: onset, progression and mortality. Neurology 17, 427-442 (1967). 214. Goetz, C.G., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19, 1020-1028 (2004). 215. Blauwendraat, C., et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging 57, 247 e249-247 e213 (2017). 216. RA, d.G. Spectral Quantification. in In Vivo MR Spectroscopy 445-477 (John Wiley & Sons, Ltd, 2007). 217. Wilson, M., et al. Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magn Reson Med 82, 527-550 (2019). 218. Cichocka, M., Kozub, J. & Urbanik, A. PH Measurements of the Brain Using Phosphorus Magnetic Resonance Spectroscopy ((31)PMRS) in Healthy Men - Comparison of Two Analysis Methods. Polish journal of radiology 80, 509-514 (2015). 219. Iotti, S., et al. In vivo assessment of free magnesium concentration in human brain by 31P MRS. A new calibration curve based on a mathematical algorithm. NMR Biomed 9, 24-32 (1996). 220. Iotti, S., Frassineti, C., Sabatini, A., Vacca, A. & Barbiroli, B. Quantitative mathematical expressions for accurate in vivo assessment of cytosolic [ADP] and DeltaG of ATP hydrolysis in the human brain and skeletal muscle. Biochim Biophys Acta 1708, 164-177 (2005). 221. Barbiroli, B., et al. Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 13, 469-474 (1993). 222. Minati, L., Aquino, D., Bruzzone, M.G. & Erbetta, A. Quantitation of normal metabolite concentrations in six brain regions by in-vivoH-MR spectroscopy. J Med Phys 35, 154-163 (2010). 223. Hangel, G., et al. Inter-subject stability and regional concentration estimates of 3D-FID-MRSI in the human brain at 7 T. NMR in Biomedicine 34, e4596 (2021). 224. Tal, A., Kirov, II, Grossman, R.I. & Gonen, O. The role of gray and white matter segmentation in quantitative proton MR spectroscopic imaging. NMR Biomed 25, 1392-1400 (2012). 225. Wright, I.C., et al. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage 2, 244-252 (1995). 226. Sarafian, M.H., et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem 87, 9662-9670 (2015). 227. Bertoni-Freddari, C., et al. Role of Mitochondrial Deterioration in Physiological and Pathological Brain Aging. Gerontology 50, 187-192 (2004). 228. Forester, B.P., et al. Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed 23, 242-250 (2010). 229. Folstein, M.F., Folstein, S.E. & McHugh, P.R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198 (1975). 230. Creavin, S.T., et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev, CD011145 (2016). 231. Allen, S.P., et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiology of Aging 35, 1499-1509 (2014). 232. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological) 57, 289-300 (1995). 233. Evans, L.D. A two-score composite program for combining standard scores. Behavior Research Methods, Instruments, & Computers 28, 209-213 (1996). 234. Yang, W., et al. Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis 6, 15 (2020). 235. Borsche, M., Pereira, S.L., Klein, C. & Grunewald, A. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis 11, 45-60 (2021). 236. Zambrano, K., et al. Fighting Parkinson's disease: The return of the mitochondria. Mitochondrion 64, 34-44 (2022). 237. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14, 795-803 (2015). 238. Cuevas, E., et al. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson's disease. Nutr Neurosci, 1-18 (2020). 239. Rosa, A.I., et al. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease. Mol Neurobiol 55, 9139-9155 (2018). 240. Moreira, S., et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. Exp Neurol 295, 77-87 (2017). 241. Goulis, J., Leandro, G. & Burroughs, A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354, 1053-1060 (1999). 242. Cole, M.H., Silburn, P.A., Wood, J.M., Worringham, C.J. & Kerr, G.K. Falls in Parkinson's disease: kinematic evidence for impaired head and trunk control. Mov Disord 25, 2369-2378 (2010). 243. Hubble, R.P., Naughton, G.A., Silburn, P.A. & Cole, M.H. Wearable sensor use for assessing standing balance and walking stability in people with Parkinson's disease: a systematic review. PLoS One 10, e0123705 (2015). 244. Payne, T., et al. Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson's disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open 10, e038911 (2020). 245. Nasreddine, Z.S., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53, 695-699 (2005). 246. Montgomery, S.A. & Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134, 382-389 (1979). 247. Chaudhuri, K.R., et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21, 916-923 (2006). 248. Richards, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17, 405-424 (2015). 249. Wolfer, A.M., et al. peakPantheR, an R package for large-scale targeted extraction and integration of annotated metabolic features in LC-MS profiling datasets. Bioinformatics 37, 4886-4888 (2021). 250. Trojaniello, D., Ravaschio, A., Hausdorff, J.M. & Cereatti, A. Comparative assessment of different methods for the estimation of gait temporal parameters using a single inertial sensor: application to elderly, post-stroke, Parkinson's disease and Huntington's disease subjects. Gait Posture 42, 310-316 (2015). 251. Spain, R.I., et al. Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture 35, 573-578 (2012). 252. Moe-Nilssen, R. & Helbostad, J.L. Estimation of gait cycle characteristics by trunk accelerometry. J Biomech 37, 121-126 (2004). 253. Galna, B., Lord, S. & Rochester, L. Is gait variability reliable in older adults and Parkinson's disease? Towards an optimal testing protocol. Gait Posture 37, 580-585 (2013). 254. Moe-Nilssen, R. A new method for evaluating motor control in gait under real-life environmental conditions. Part 1: The instrument. Clin Biomech 13, 320-327 (1998). 255. Angelini, L., et al. Is a Wearable Sensor-Based Characterisation of Gait Robust Enough to Overcome Differences Between Measurement Protocols? A Multi-Centric Pragmatic Study in Patients with Multiple Sclerosis. Sensors 20, 79 (2019). 256. Salarian, A., et al. Gait assessment in Parkinson's disease: toward an ambulatory system for long-term monitoring. IEEE Trans Biomed Eng 51, 1434-1443 (2004). 257. Ordidge, R.J., Connelly, A. & Lohman, J.A.B. Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy. J Magn Reson 66, 283-294 (1986). 258. Ordidge, R.J., Bowley, R.M. & McHale, G. A general approach to selection of multiple cubic volume elements using the ISIS technique. Magn Reson Med 8, 323-331 (1988). 259. Stefan, D., et al. Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package. Meas Sci Technol 20(2009). 260. de Graaf, R.A. Spectral Quantification. in In Vivo NMR Spectroscopy 439-471 (John Wiley & Sons, Ltd., 2019). 261. Iotti, S. & Malucelli, E. In vivo assessment of Mg2+ in human brain and skeletal muscle by 31P-MRS. Magnes Res 21, 157-162 (2008). 262. Schmitz, B., et al. Effects of Aging on the Human Brain: A Proton and Phosphorus MR Spectroscopy Study at 3T. J Neuroimaging 28, 416-421 (2018). 263. Athauda, D., et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664-1675 (2017). 264. Goetz, C.G., et al. Handling missing values in the MDS-UPDRS. Mov Disord 30, 1632-1638 (2015). 265. Ward, A., Brogden, R.N., Heel, R.C., Speight, T.M. & Avery, G.S. Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs 27, 95-131 (1984). 266. Simuni, T., et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 78, 312-320 (2021). 267. Pagan, F.L., et al. Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol 77, 309-317 (2020). 268. Vaz, A.R., et al. Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid. J Neurochem 112, 56-65 (2010). 269. Brito, M.A., et al. Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology 29, 259-269 (2008). 270. Li, H., et al. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 12, 788558 (2021). 271. Tang, R., et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67, 534-541 (2018). 272. Whone, A., et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain 142, 512-525 (2019). 273. Kieburtz, K., Katz, R., McGarry, A. & Olanow, C.W. A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic. Mov Disord 36, 59-63 (2021). 274. Mico-Amigo, M.E., et al. Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. Front Hum Neurosci 13, 59 (2019). 275. Hobert, M.A., et al. Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. Front Aging Neurosci 11, 22 (2019). 276. Amboni, M., et al. Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. J Neurol 265, 2211-2220 (2018). 277. Galna, B., Lord, S., Burn, D.J. & Rochester, L. Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Mov Disord 30, 359-367 (2015). 278. van der Heide, A., Meinders, M.J., Bloem, B.R. & Helmich, R.C. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson's Disease. J Parkinsons Dis 10, 1355-1364 (2020). 279. Pissadaki, E.K. & Bolam, J.P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci 7, 13 (2013). 280. Mullin, S., et al. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol 77, 427-434 (2020). 281. Chong, R., et al. Niacin Enhancement for Parkinson's Disease: An Effectiveness Trial. Front Aging Neurosci 13, 667032 (2021). 282. Patel, D. & Witt, S.N. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. Oxid Med Cell Longev 2017, 4829180 (2017). 283. Osman, C., Voelker, D.R. & Langer, T. Making heads or tails of phospholipids in mitochondria. J Cell Biol 192, 7-16 (2011). 284. Riekkinen, P., Rinne, U.K., Pelliniemi, T.-T. & Sonninen, V. Interaction Between Dopamine and Phospholipids: Studies of the Substantia Nigra in Parkinson Disease Patients. Archives of Neurology 32, 25-27 (1975). 285. Chang, K.-H., et al. Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson's Disease. Cells 11, 395 (2022). 286. Manyam, B.V., Ferraro, T.N. & Hare, T.A. Cerebrospinal Fluid Amino Compounds in Parkinson's Disease: Alterations due to Carbidopa/Levodopa. Archives of Neurology 45, 48-50 (1988). 287. Brockmann, K., et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 79, 213-220 (2012). 288. Bell, S.M., et al. Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future? Biomedicines 9(2021). 289. Shi, X.-F., et al. Decreased brain PME/PDE ratio in bipolar disorder: a preliminary 31P magnetic resonance spectroscopy study. Bipolar Disorders 17, 743-752 (2015). 290. Haszto, C.S., Stanley, J.A., Iyengar, S. & Prasad, K.M. Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies. Biol Psychiatry Cogn Neurosci Neuroimaging 5, 264-280 (2020). 291. Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H.R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson's disease. The Lancet Neurology 20, 559-572 (2021). 292. Parker, W.D., Jr., Parks, J.K. & Swerdlow, R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 1189, 215-218 (2008). 293. Murphy, K.E., et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137, 834-848 (2014). 294. Rakovic, A., et al. Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS One 6, e16746 (2011). 295. Iles, R.A., Stevens, A.N., Griffiths, J.R. & Morris, P.G. Phosphorylation status of liver by 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n.m.r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 229, 141-151 (1985). 296. Meyerspeer, M., et al. 31P magnetic resonance spectroscopy in skeletal muscle: Experts' consensus recommendations. NMR in Biomedicine 34, e4246 (2021). 297. Lesage, S., et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73, 459-471 (2013). 298. Pankratz, N., et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 73, 279-286 (2009). 299. Lyamzaev, K.G., et al. Induction of autophagy by depolarization of mitochondria. Autophagy 14, 921-924 (2018). 300. Ivankovic, D., Chau, K.Y., Schapira, A.H. & Gegg, M.E. Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin-mediated mitophagy. J Neurochem 136, 388-402 (2016). 301. Andres, R.H., Ducray, A.D., Schlattner, U., Wallimann, T. & Widmer, H.R. Functions and effects of creatine in the central nervous system. Brain Res Bull 76, 329-343 (2008). 302. Das, N., Ren, J., Spence, J.S., Rackley, A. & Chapman, S.B. Relationship of Parieto-Occipital Brain Energy Phosphate Metabolism and Cognition Using (31)P MRS at 7-Tesla in Amnestic Mild Cognitive Impairment. Frontiers in aging neuroscience 12, 222-222 (2020). 303. von Bartheld, C.S., Bahney, J. & Herculano-Houzel, S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. J Comp Neurol 524, 3865-3895 (2016). 304. Yakhine-Diop, S.M.S., et al. Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson's Disease Patients. Mol Neurobiol 56, 2466-2481 (2019). 305. Matsuda, N., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189, 211-221 (2010). 306. Diano, S., et al. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology 144, 5014-5021 (2003). 307. Bloem, B.R., Okun, M.S. & Klein, C. Parkinson's disease. The Lancet 397, 2284-2303 (2021). 308. Grunewald, A., Kumar, K.R. & Sue, C.M. New insights into the complex role of mitochondria in Parkinson's disease. Prog Neurobiol 177, 73-93 (2019). 309. Payne, T., et al. 31Phosphorus magnetic resonance spectroscopy in Parkinson’s disease demonstrates relationships with predicted disease progression and mitochondrial dysfunction in the peripheral tissue. (Mansucript in preparation for submission to Annals of Neurology, 2022). 310. van der Heeden, J.F., et al. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 86, 2243 (2016). 311. Lawson, R.A., et al. Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort. Journal of Parkinson's disease 11, 1297-1308 (2021). 312. Williams-Gray, C.H., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132, 2958-2969 (2009). 313. Haszto, C.S., Stanley, J.A., Iyengar, S. & Prasad, K.M. Regionally Distinct Alterations in Membrane Phospholipid Metabolism in Schizophrenia: A Meta-analysis of Phosphorus Magnetic Resonance Spectroscopy Studies. Biol Psychiatry Cogn Neurosci Neuroimaging 5, 264-280 (2020). 314. Combs, H.L., Wyman-Chick, K.A., Erickson, L.O. & York, M.K. Development of standardized regression-based formulas to assess meaningful cognitive change in early Parkinson’s disease. Archives of Clinical Neuropsychology 36, 734-745 (2021). 315. Eickhoff, C.R., et al. Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. Brain Commun 3, fcab191-fcab191 (2021). 316. Ward, C.D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57, 217-220 (1994). 317. Group, T.P.S. Cerebrospinal Fluid Homovanillic Acid in the DATATOP Study on Parkinson's Disease. Archives of Neurology 52, 237-245 (1995). 318. Simon, D.K., et al. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis 5, 731-736 (2015). 319. de Lau, L.M., Koudstaal, P.J., Hofman, A. & Breteler, M.M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58, 797-800 (2005). 320. Athauda, D., et al. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. JAMA Neurol 76, 420-429 (2019). 321. Horvath, K., et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord 21, 1421-1426 (2015). 322. Carroll, C.B., et al. Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study. BMJ Open 9, e029740 (2019). 323. Mazzà, C., et al. Technical validation of real-world monitoring of gait: a multicentric observational study. BMJ open 11, e050785-e050785 (2021). 324. Kimmeskamp, S. & Hennig, E.M. Heel to toe motion characteristics in Parkinson patients during free walking. Clinical Biomechanics 16, 806-812 (2001). 325. Raffegeau, T.E., et al. A meta-analysis: Parkinson's disease and dual-task walking. 326. Del Din, S., Godfrey, A., Mazzà, C., Lord, S. & Rochester, L. Free-living monitoring of Parkinson's disease: Lessons from the field. Movement Disorders 31, 1293-1313 (2016). 327. Lo, C., et al. A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease. Journal of Neurology, Neurosurgery &amp; Psychiatry 93, 617 (2022). 328. Wu, C.A.-O., et al. Responsiveness, Minimal Clinically Important Difference, and Validity of the MoCA in Stroke Rehabilitation. 329. Skorvanek, M., et al. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. 330. Rittman, T., et al. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. 331. Lucza, T.A.-O.X., et al. Comparing Sensitivity and Specificity of Addenbrooke's Cognitive Examination-I, III and Mini-Addenbrooke's Cognitive Examination in Parkinson's Disease. 332. Vijiaratnam, N.A.-O., et al. Combining biomarkers for prognostic modelling of Parkinson's disease. 333. Greenland, J.C., Williams-Gray, C.H. & Barker, R.A. The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci (2018). 334. Espay, A.J., et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord 32, 319-324 (2017). 335. Bingol, B., et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 510, 370-375 (2014). 336. Pettegrew, J.W., Panchalingam, K., Klunk, W.E., McClure, R.J. & Muenz, L.R. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 15, 117-132 (1994). 337. Ross, A.J. & Sachdev, P.S. Magnetic resonance spectroscopy in cognitive research. Brain Research Reviews 44, 83-102 (2004). 338. Pavese, N. & Tai, Y.F. Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. Movement disorders clinical practice 5, 131-140 (2018). 339. Cuenoud, B., et al. Brain NAD Is Associated With ATP Energy Production and Membrane Phospholipid Turnover in Humans. Frontiers in aging neuroscience 12, 609517-609517 (2020). 340. Deus, C.M., et al. Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects. Biochim Biophys Acta Mol Basis Dis 1866, 165615 (2020). 341. Lapasset, L., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 25, 2248-2253 (2011). 342. Chang, C.-K., et al. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo (1)H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome. Diagnostics (Basel) 11, 1541 (2021)."],"dcterms:accessrights":["public"],"dc:title":["Mitochondrial dysfunction as a therapeutic target in Parkinson's Disease"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["doctoral"],"dc:type.qualificationname":["Ph.D"],"person:identifier.orcid":["0000000167537847"]},"updated_at":"2026-11-18T23:19:31Z"}